Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib plus Letrozole in Neoadjuvant HR+/HER2- Breast Cancer
NCT05512780Phase 2Unknown
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of dalpiciclib in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05512780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05512780.